Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.

Patients with advanced or metastatic non–small cell lung cancer (NSCLC) were able to specify a 1-point threshold when describing meaningful symptom change, for better or worse, that helped ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

We must come together to combat air pollution and move to clean energy to prevent more needless deaths from lung cancer.

With 44,000 new diagnoses each year, non-small cell lung cancer is the second most frequent neoplasm in Italy after breast ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

The findings suggest that reconsideration of current clinical guidelines, which support MRI only for symptomatic brain ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...